Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI)
Company Research
Source: GlobeNewswire
SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of its initial public offering of 69,000,000 shares of Class A common stock, including the full exercise of the underwriters’ option to purchase up to 9,000,000 additional shares of Class A common stock, at a public offering price of $27 per share. The aggregate gross proceeds to Maravai from the offering were approximately $1,863,000,000, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Maravai. Maravai’s Class A common stock began trading on the Nasdaq Global Select Market on November 20, 2020 under the symbol "MRVI." Morgan Stanley, Jefferies and Goldman Sachs & Co. LLC acted as joint book-running managers for the offering. BofA Securities, Credit Suisse, UBS Investment Bank, B
Show less
Read more
Impact Snapshot
Event Time:
MRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRVI alerts
High impacting Maravai LifeSciences Holdings, Inc. - Class A common stock news events
Weekly update
A roundup of the hottest topics
MRVI
News
- TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production [Yahoo! Finance]Yahoo! Finance
- TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance ProductionBusiness Wire
- Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024GlobeNewswire
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $15.00 price target on the stock.MarketBeat
- Should You Sell Maravai LifeSciences (MRVI)? [Yahoo! Finance]Yahoo! Finance
MRVI
Earnings
- 2/22/24 - Beat
MRVI
Sec Filings
- 4/16/24 - Form 4
- 3/18/24 - Form 4
- 3/18/24 - Form 4
- MRVI's page on the SEC website